A new treatment that redirects the body’s immune system to kill cancer cells may offer hope to patients whose cancers have stopped responding to other treatments. Researchers at the Institute of Cancer Research and Royal Marsden NHS Foundation Trust say the new immunotherapy drug AFM24 is still highly experimental and trials are at an early stage but the team are “highly excited by its potential”. NB the research is on a number of cancers, not specifically for prostate cancer cells.  The Times 9 April 2022.